VC banks on CAR T through acoustic wave separation firm investment

By Dan Stanton contact

- Last updated on GMT

GettyImages/BackyardProduction
GettyImages/BackyardProduction

Related tags: Chemical engineering

Venture capital company Dynamk Capital has invested in FloDesign Sonics citing its acoustic wave separation technology’s application in the growing CAR T cell sector.

The New Jersey-based life sciences backer has added FloDesign Sonics (FDS) to its portfolio, describing the investment as an entry into commercial CAR T and immunotherapy production advancement.

“FloDesign Sonics is fundamentally changing cell selection, handling and separation through application of gentle acoustic processing,”​ said Daniella Kranjac, co-founder and managing director of Dynamk Capital.

“We are thrilled to see the commercialisation of this technology in bioprocessing, and now FDS is set to innovate cell and gene therapy delivery, reducing cost and improving access to life-saving therapies, by enabling closed, automated, and gentle cell processing.”

Enabling the fourth pillar of modern medicine’

The firm’s acoustic wave separation (AWS) system uses a three-dimensional standing wave to trap and gather cells in the flow channel through a process called acoustophoresis. This allows particle separations that are more typically performed with porous filters or centrifuges but offers low-power, no-pressure-drop, no-clog, and no-shear, according to the company.

The platform was licensed by Pall in 2015​ as an alternative to tangential-flow filtration (TFF) and alternating tangential flow (ATF) in perfusion technologies, and more recently the firm has been pushing the tech towards cell and gene therapy applications.

Last September, FDS founder and CEO Stanley Kowalski spoke with Biopharma-Reporter on the back of a co-development deal with an undisclosed large biopharmaceutical firm to commercialise the acoustic-based unit operations in both concentration-wash and acoustic affinity cell separation (AACS) for production of a CAR T candidate.

“We believe we are really going to enable the CAR T therapies to lower the cost,”​ he told us at Biotech Week Boston. “We like to say we are enabling the fourth pillar of modern medicine.”

Related news

Show more

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Related suppliers

Follow us

Products

View more

Webinars